Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

Biswas, Partha; Sengupta, Subhrangshu; Choudhary, Ruby; Home, Subhankar; Paul, Ajoy; Sinha, Sourav
May 2011
Indian Journal of Ophthalmology;May2011, Vol. 59 Issue 3, p191
Academic Journal
Context: Ranibizumab and bevacizumab are used widely for treating patients with choroidal neovascular membrane (CNVM) secondary to age-related macular degeneration (AMD). Aims: To determine and compare the efficacy and safety of intravitreal ranibizumab and bevacizumab in treatment of CNVM due to AMD. Settings and Design: Prospective comparative case series carried out in an eye institute and eye department of a hospital in Kolkata, India. Materials and Methods: One hundred and four eyes with CNVM due to AMD were randomized into two groups. Group A (n=54; 24 occult) received monthly intravitreal ranibizumab injections (0.5 mg in 0.05 ml) and Group B (n=50; 22 occult) received monthly bevacizumab injections (1.25 mg in 0.05 ml) for 3 consecutive months and then as per study criteria. Data analysis done using SPSS software. P-value of <0.05 was considered statistically significant. Results: The mean best corrected visual acuity (BCVA) in the ranibizumab group increased from 58.19 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at baseline to 64 ETDRS letters at month 3 (P<0.001). In bevacizumab group mean BCVA increased from 56.80 to 61.72 ETDRS letters at month 3 (P<0.001). At the end of 18 months, there was no statistically significant difference between groups A and B with respect to change in BCVA (P=0.563) or central macular thickness (CMT; P=0.281), as measured by optical coherence tomography (Stratus OCT 3000). No significant sight-threatening complications developed. Conclusions: Ranibizumab and bevacizumab are equally safe and efficacious in treating CNVM due to AMD.


Related Articles

  • Where the AMD Clinical Trials Stand. Ciulla, Thomas A.; Regillo, Carl // Review of Ophthalmology;Jan2001, Vol. 8 Issue 1, p58 

    Examines the accuracy of various therapies for age-related macular degeneration (AMD) in Indianapolis, Indiana. Role of nutrition in AMD; Improvement in visual acuity following laser treatment of drusen; Use of photodynamic therapy in activating intravascular dyes for vascular occlusion;...

  • Panel recommends aflibercept. Heier, Jeffrey s.; Krader, Cheryl Guttman // Ophthalmology Times;7/1/2011, Vol. 36 Issue 13, p1 

    The article discusses the intravitreal aflibercept by Regeneron Pharmaceuticals Inc. for the treatment of neovascular age-related macular degeneration (AMD) which is still subjected to U.S. Food and Drug Administration (FDA) approval. It notes that the result of the review conducted by the...

  • Interim results: Insert shows benefit as DME treatment. Groves, Nancy // Ophthalmology Times;11/1/2009, Vol. 34 Issue 21, p36 

    The article reports on the result of a pharmacokinetic study which suggests that both the high and low dosage versions of the investigational fluocinolone acetonide intravitreal insert, indicate a benefit visual acuity in treating diabetic macular edema (DME). According to Dr. Thomas A. Ciulla,...

  • Ä°ntravitreal Ranibizumab Enjeksiyonu Uygulanan Diabetik Maküla Ödemli Olgularda Görme KeskinliÄŸini Etkileyen Faktörler. SELEN, Fırat; DEMİREL, Sibel; BATIOĞLU, Figen; ÖZMERT, Emin // Retina-Vitreus/Journal of Retina-Vitreous;Dec2013, Vol. 21 Issue 4, p269 

    Purpose: To evaluate the factors associated with visual acuity after treatment of diabetic macular edema with intravitreal ranibizumab. Materials and Methods: 53 eyes of 37 patients with macular edema secondary to diabetic retinopathy were treated with 0.5 mg intravitreal ranibizumab injections...

  • Intravitreal Bevacizumab (Avastin) in Treatment of Neovascular Age-related Macular Degeneration. Lazić, Ratimir; Gabrić, Nikica; Dekaris, Iva; Šarić, Borna; Gavrić, Morena // Collegium Antropologicum;2007 Supplement 1, Vol. 31 Issue s1, p77 

    To evaluate the efficacy and safety of intravitreal bevacizumab in treatment of minimally classic and occult choroidal neovascularization secondary to age-related macular disease 48 eyes of 48 patients (mean age of 74.8) included in this prospective, noncomparative, interventional case series....

  • Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK. Buckle, Miranda; Donachie, Paul H. J.; Johnston, Robert L. // British Journal of Ophthalmology;Feb2016, Vol. 100 Issue 2, p240 

    Aims To study long-term, whole population 'real-world' clinical outcomes of ranibizumab therapy in treatment-naïve eyes for neovascular age-related macular degeneration. Methods Data collected prospectively from a single centre serving a defined population using an electronic medical record...

  • Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4). Sivaprasad, Sobha; Crosby-Nwaobi, Roxanne; Esposti, Simona; Peto, Tunde; Rajendram, Ranjan; Michaelides, Michel; Hykin, Philip // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Background: To describe structural and functional changes associated with diabetic macular oedema (DMO) treated with intravitreal bevacizumab over 24 months. Methods: A post-hoc analysis of the data of 34 patients that completed 24 months follow-up in the intravitreal bevacizumab arm of a...

  • What Do AMD Patients and Caregivers Need to Know about the Telescope Implant For End-Stage Age-Related Macular Degeneration?  // Braille Forum;Sep2013, Vol. 52 Issue 3, p13 

    The article offers information on the telescope implant, an alternative treatment for American patients with end-stage age-related macular degeneration (AMD). It says that CentraSight treatment program is designed to help AMD patient to improve their vision and quality of life by implanting a...

  • Macular hole surgery now more than 80% successful. Charters, Lynda; Thompson, John T. // Ophthalmology Times; 

    Focuses on macular hole surgery. Vitreoretinal surgical procedures for restoring visual acuity in eyes with macular disease; Cystoid macular edema; Most important prognostic indicator of visual outcome in macular holes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics